Biologics & ABPA - what are they and what can they do?
Biologic medications (also known as biologics) are a class of drugs derived from living organisms or their cells. These treatments are used for various conditions, especially those involving the immune system, such as autoimmune diseases, cancers, and chronic inflammatory disorders. Here’s a breakdown of biologics:
1. What Are Biologics?
- Biologics are large, complex molecules made using biotechnology. They can be derived from living organisms such as bacteria, yeast, or animal cells.
- Unlike traditional medications (chemically synthesized), biologics are produced through genetic engineering or cell culture techniques.
2. Types of Biologic Drugs:
- Monoclonal Antibodies (mAbs): These are engineered antibodies designed to target specific proteins or cells, such as tumor cells or immune system components. Examples include drugs like adalimumab (Humira) for rheumatoid arthritis and rituximab (Rituxan) for certain cancers.
- Interferons: Proteins that modify immune system activity. They are used for conditions like multiple sclerosis and hepatitis C.
- Vaccines: Biologic drugs used to stimulate the immune system to protect against infectious diseases (e.g., the flu vaccine, COVID-19 vaccines).
- Cell and Gene Therapies: These involve altering genes or using stem cells to treat genetic disorders or cancers. CAR T-cell therapies are an example for cancer treatment.
3. Conditions Treated by Biologics:
- Autoimmune Disorders: Such as rheumatoid arthritis, Crohn’s disease, and psoriasis.
- Cancer: Biologics like monoclonal antibodies and immune checkpoint inhibitors target cancer cells.
- Infections: Some biologics, including vaccines, protect against infections like hepatitis, flu, and COVID-19.
- Chronic Inflammatory Conditions: Such as asthma and inflammatory bowel disease (IBD).
4. Advantages of Biologics:
- Targeted Action: Biologics can target specific parts of the immune system or cells involved in disease, leading to more effective treatments with fewer side effects compared to traditional drugs.
- Personalized Treatments: Some biologics can be customized based on a patient's genetics, improving outcomes for certain conditions.
5. Limitations and Side Effects:
- Expensive: Biologics tend to be more expensive than traditional medications due to the complex production process.
- Injection or Infusion: Many biologics are administered through injections or intravenous infusions rather than oral tablets.
- Immune System Effects: Since biologics modify immune system function, they can increase the risk of infections and other immune-related side effects.
Examples of Biologic Medications:
- Humira (adalimumab) for autoimmune diseases.
- Keytruda (pembrolizumab) for cancer treatment.
- Enbrel (etanercept) for rheumatoid arthritis.
Biologics are reshaping the treatment landscape, particularly in conditions where traditional medications were less effective.
In the case of Allergic Bronchopulmonary Aspergillosis (ABPA), biologic medications are increasingly being explored and used as part of treatment, particularly for patients with more severe or resistant forms of the disease. ABPA is an allergic reaction to the fungus Aspergillus, which can lead to airway inflammation and lung damage. Biologic medications, often aimed at modulating the immune system, help in managing this complex condition, especially when conventional treatments like corticosteroids fail to control symptoms or lead to significant side effects.
How Biologics Help in ABPA Treatment:
- Targeting Immune System Pathways:
- Biologics used in ABPA primarily work by targeting specific immune system pathways that drive the inflammatory response triggered by the Aspergillus fungus.
- For example, biologics that target interleukin-5 (IL-5), such as mepolizumab (Nucala), can help reduce eosinophil levels, a type of white blood cell involved in allergic reactions and inflammation in ABPA. Dupixent, another biologic, targets IL-4 and IL-13, which are cytokines involved in the inflammatory cascade in ABPA, potentially improving lung function and reducing exacerbations .
- Omalizumab (Xolair) acts directly on the patients IgE antibodies, preventing them triggering allergic inflammation
- Reducing Steroids - For ABPA patients who require long-term corticosteroid use, biologics may offer an alternative, reducing dependence on steroids and lowering the risk of long-term steroid side effects (e.g., osteoporosis, diabetes, and weight gain).
- Biologics can provide a more targeted approach, addressing the underlying immune mechanism, rather than just suppressing the overall immune response with steroids .
- Clinical Evidence:
- In trials, biologics like mepolizumab have shown improvements in asthma control and reduced exacerbations, suggesting potential benefits for ABPA patients with significant asthma components.
- Dupilumab has also demonstrated potential benefits in patients with ABPA and associated asthma, showing improvements in lung function and reduction in eosinophil levels, thus addressing both the underlying inflammation and allergic reactions .
- Safety and Efficacy:
- While biologics are typically used in cases where standard treatments (steroids, antifungals) are not sufficient or appropriate. These medications are generally well-tolerated, but they do carry risks, such as increased susceptibility to infections due to immune system modulation** .
Summary:
Biologic therapies represent an option for patients with ABPA, particularly those with severe symptoms or who struggle with long-term steroid use. By targeting specific immune pathways, biologics help reduce inflammation and improve lung function without the broad immunosuppression of steroids. Drugs like mepolizumab and dupilumab are showing encouraging results, though their use in ABPA is still being refined and evaluated in clinical trials.
If you're exploring biologics for ABPA treatment, consulting with a specialist in pulmonary or immunologic disorders is crucial, as the benefits and risks of these drugs need to be carefully balanced for each individual patient.
**One common concern is whether these treatments could increase susceptibility to viral infections, particularly respiratory viruses.
Immune Modulation and Viral Infections: Omalizumab (Anti-IgE): Omalizumab reduces IgE levels, which are primarily involved in allergic reactions, not antiviral immunity. Studies show that it may actually decrease the frequency of respiratory viral infections by reducing inflammation and preventing exacerbations triggered by viruses. In clinical trials, omalizumab was not associated with increased viral infection rates and has been shown to lower asthma exacerbations caused by viral infections.
Mepolizumab and Benralizumab (Anti-IL-5): These biologics target IL-5, which reduces eosinophil counts. Eosinophils play a minor role in viral defense, but their reduction does not seem to impair the body's ability to fight viruses significantly. Data suggest that mepolizumab and benralizumab do not increase the incidence of viral infections and can reduce asthma exacerbations, including those triggered by viruses.
Dupilumab (Anti-IL-4/IL-13): Dupilumab inhibits IL-4 and IL-13 signaling, key cytokines in allergic inflammation. It is not associated with increased viral infection susceptibility in clinical trials. It may enhance antiviral defenses by reducing Th2-skewed inflammation, potentially allowing the body to mount a better response to viruses.
Evidence from Studies: Studies have consistently shown that biologics can reduce asthma exacerbations, many of which are triggered by viral infections, suggesting they do not compromise the immune system's ability to fight viruses. No significant increase in viral infections has been observed in large clinical trials for these medications, and they are generally considered safe in this context.
Conclusion: Biologic medications for asthma do not appear to increase vulnerability to viral infections. In fact, they may reduce the risk of virus-induced asthma exacerbations by controlling airway inflammation. However, patients with severe asthma or comorbid conditions should always consult their healthcare provider regarding potential risks.
Olorofim - a promising new antifungal candidate for aspergillosis treatment.
Olorofim represents a significant advancement in treating aspergillosis, particularly for patients who cannot tolerate or do not respond to existing antifungal therapies. Here’s why it’s important:
1. Novel Mechanism of Action
- Olorofim is the first antifungal in a new class called orotomides. It inhibits dihydroorotate dehydrogenase, an enzyme essential for fungal pyrimidine biosynthesis.
- This mechanism is entirely distinct from existing antifungal classes (azoles, polyenes, and echinocandins), making it effective against strains resistant to current treatments
2. Broad Spectrum and Potency
- It has demonstrated activity against azole-resistant Aspergillus species and other difficult-to-treat moulds, addressing a major gap in antifungal therapy
-
This includes rare and often lethal fungal infections like Scedosporium, Lomentospora, and Fusarium, as well as chronic conditions like Chronic Pulmonary Aspergillosis (CPA) and invasive aspergillosis.
3. Oral Administration
- Unlike many current treatments that require intravenous administration (e.g., amphotericin B), olorofim is taken orally, improving convenience and accessibility for patients needing long-term therapy.
4. Targeting Unmet Needs
- Aspergillosis, particularly invasive aspergillosis, has high morbidity and mortality rates, especially in immunocompromised patients (e.g., those with cancer, transplant recipients).
- Current treatments face challenges like resistance, toxicity, and drug-drug interactions. Olorofim addresses these limitations by offering a safer and more tolerable alternative
5. Regulatory Recognition
- The drug has been granted Breakthrough Therapy Designation and Orphan Drug Status by the FDA and EMA, underscoring its potential to meet urgent medical needs
Future Implications
Olorofim's availability for treating Chronic Pulmonary Aspergillosis (CPA) depends on its successful progression through clinical trials and regulatory approval. Here's a summary of its current status and potential timeline:
- Current Status:
- Olorofim is in Phase 3 clinical trials (OASIS trial) for invasive fungal diseases, including invasive aspergillosis, a related but more acute condition than CPA.
- Although the drug has shown promising results in earlier studies, the FDA recently issued a Complete Response Letter, indicating that additional clinical data is required before it can be approved in the U.S.
- CPA is not explicitly listed as a primary indication in current trials, but success in related aspergillosis treatments could lead to future trials or off-label use for CPA.
- Timeline to Approval:
- If the ongoing Phase 3 trial and additional studies satisfy regulatory agencies, olorofim could receive an approval within 2–3 years for its initial indications (e.g., invasive aspergillosis).
- For CPA specifically:
- Additional trials may be needed to confirm efficacy and safety, potentially extending approval timelines by 3–5 years.
- Off-label use might occur sooner, depending on clinician judgment and availability in regions with less restrictive policies.
Given the high unmet need in CPA and the novelty of olorofim’s mechanism, it is closely watched by both the medical community and regulators. If you're a patient with CPA, keeping in touch with your healthcare provider about ongoing trials and compassionate use programs may help you access new treatments sooner.
UK National RSV vaccination program launched
Respiratory Syncytial Virus (RSV) is mostly a minor ‘common cold’ for us, but for the very young and the elderly, it can cause severe infections eg pneumonia. Each year it can cause 30,000 hospitalisations and 20-30 deaths amongst infants, whilst amongst the elderly it can cause around 9,000 hospital admissions, mostly in those aged over 75.
Conversations with a few of our aspergillosis patients suggest that this is a point of concern for them as although asthma & aspergillosis is not specifically mentioned as a risk factor for infection, many have young children or grandchildren who they are wary of visiting during the winter months for fear of catching an RSV infection.
RSV infections usually peak during the winter months in the UK.
We now have two new vaccines available to help prevent infection and hospitalisation, and the UK government has opted to introduce a nationwide program to vaccinate the most vulnerable i.e. pregnant women to protect the child after birth and those aged 75-79. The program will start in Scotland on 18th August and 1st September for England, Wales and N. Ireland.
For full details go here
CPA patients have impaired neutrophil response to infection
A new paper from a research group in India has compared people who have tuberculosis (Tb) with those who have Tb and then developed chronic pulmonary aspergillosis (CPA). CPA develops in patients with Tb quite commonly and for many years it has been speculated that the mould grows on the lung scar tissue left behind by a Tb infection.
The researchers looked at many components of the patient’s immune system to try to see if any differed between the two as this would potentially tell them why one patient might develop CPA while another doesn’t.
Significantly the research team found that those patients who went on to develop CPA had reduced intensity of ‘neutrophil burst’, which is the release of reactive oxygen chemicals that are important in the fight against infection. They also had impaired Th1 cell response which is important as Th1 cells are part of the patient’s normal response to infection and they produce cytokines like interferon-gamma (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-alpha (TNF-α). In turn, these trigger cytokines activate macrophages, enhance the phagocytic (pathogen-eating!) ability of immune cells, and stimulate the production of antibodies that mark pathogens for attack.
In short, we now have a clearer understanding of at least one part of the immune system of a CPA patient that isn’t working as well as it should, and which would directly lead to them being more vulnerable to infection.
The next question is ‘why are these patients unable to produce the normal levels of neutrophil burst and Th1 cell response?’ There are several possibilities including:
-
- Genetic disorder
- Immunosuppressive medication
- Chronic diseases eg diabetes, renal failure, liver disease
- Malnutrition/eg Vitamin D deficiency
- Alcohol abuse
- Severe infection
- HIV
- Exposure to some toxins (eg mercury, lead
- Autoimmune disorder
Some of these may apply to the patients in this study but it is not yet clear which are the most likely. There is more work to do!
What does this mean for treatment of CPA?
The INCAS study, sets out to assess if CPA patients benefit when they are given supplementary doses of interferon-gamma. This is one of the cytokines found to be inhibited in CPA patients in the study discussed above, so if these patients improve it is good evidence that we have found one of the important causes of susceptibility to CPA, and we will already have a medication to partly treat it.
English prescription charge to rise 1st May 2024
Charges for prescriptions and prescription prepayment certificates (PPCs) will increase by 2.59% (rounded to the nearest 5 pence) from 1 May 2024. Charges for wigs and fabric supports will increase by the same rate.
A prescription will cost £9.90 for each medicine or appliance dispensed, an increase of 25 pence. The 3-month PPC will cost £32.05 and the 12-month PPC will cost £114.50.
The hormone replacement therapy (HRT) PPC will cost £19.80, an increase of 50 pence. This is because the rate is set at twice the single prescription charge.
Check what help you could get to pay for NHS costs
The Role of Speech & Language Therapy (SALT)
Did you know Speech and language therapists (SLTs) play a crucial role in the management of patients with respiratory conditions?
The Royal College of Speech and Language Therapists (RCSLT) comprehensive factsheet on Upper Airway Disorders (UADs), is an essential guide designed for patients managing chronic respiratory conditions such as CPA, ABPA, COPD, asthma, and bronchiectasis. This resource aims to highlight the often-overlooked possibility of co-existing upper airway disorders, which can significantly complicate the management and treatment outcomes of these chronic respiratory diseases.

Within these pages, you will find detailed insights into the symptoms, diagnostic challenges, and effective management strategies for UADs. The leaflet emphasises the critical role of Speech and Language Therapists (SLTs) in assessing and treating these disorders. SLTs are key to providing targeted interventions that can alleviate symptoms and improve daily life.
This leaflet also aims to raise awareness amongst clinicians about the importance of considering UADs in the differential diagnosis of respiratory conditions. Enhanced understanding of these disorders can lead to better patient outcomes and improved quality of life.
To access the leaflet, click here.
Understanding How Our Lungs Fight Fungus
Airway epithelial cells (AECs) are a key component of the human respiratory system: The first line of defence against airborne pathogens such as Aspergillus fumigatus (Af), AECs play a crucial role in initiating host defence and controlling immune responses and are important in maintaining respiratory health and preventing infections that can lead to conditions such as aspergillosis. Research by the University of Manchester’s Dr Margherita Bertuzzi and her team sought to understand how AECs combat Af and what leads to vulnerabilities in these defences, particularly in individuals with underlying health conditions.
Previous work by Dr Bertuzzi and her team demonstrated that AECs are effective in stopping the fungus from causing harm when they are functioning well. However, in people who are at higher risk, like those with weakened immune systems or existing lung conditions, if these cells are not working correctly, the fungus can take advantage of this situation.
This new research by Dr Bertuzzi and her team aimed to explore how AECs stop the fungus in healthy people and what goes wrong in people who get sick. The team looked closely at the interaction between the fungus and lung cells from both healthy individuals and those with certain diseases. Using advanced scientific methods, the team was able to observe the interactions between the lung cells and the fungus at a very detailed level.
What They Found
Experiments showed that the stage of fungal growth was important and a surface carbohydrate – mannose (a sugar) also had a role in the process.
Specifically, they discovered that the fungus is more likely to be taken up by lung cells when it has been growing for a few hours compared to when it’s just a fresh spore. Swollen fungal spores that were locked at 3 and 6 hours of germination were 2-fold more readily internalised than those locked at 0 hours. They also identified that a sugar molecule called mannose on the surface of the fungus plays a big role in this process.
Mannose is a type of sugar molecule that can be found on the surface of various cells, including those of pathogens like Aspergillus fumigatus. This sugar plays an important role in the interactions between the fungus and the host’s cells, particularly the AECs lining the lungs. In a healthy immune response, mannose on the surface of pathogens can be recognised by mannose receptors on immune cells, triggering a series of immune responses aimed at eliminating the pathogen. However, Aspergillus fumigatus has evolved to exploit this interaction, allowing it to adhere to and invade lung cells more effectively. The presence of mannose on the fungus’ surface facilitates its binding to mannose-binding lectins (MBLs) (proteins that bind specifically to mannose) on the surface of lung cells. This binding can promote the internalisation of the fungus into the lung cells, where it can reside and potentially cause infection.
The research highlighted the possibility of manipulating this interaction as a means to combat fungal infections. By adding mannose or mannose-binding lectins like Concanavalin A, researchers could significantly reduce the fungus’s ability to invade lung cells. This reduction was accomplished by essentially “competing” with the fungus for the binding sites on the lung cells or by directly blocking the fungal mannose, thereby inhibiting the interaction that facilitates fungal infection.
Why does it matter?
Understanding these interactions gives us important insights into how our lungs protect us from fungal infections and what goes wrong in people who are vulnerable to such infections. This knowledge could help in creating new treatments against pathogens like Aspergillus fumigatus.
You can read the full abstract here.
Chronic illness diagnosis and guilt
Living with a chronic disease can often lead to feelings of guilt, but it's important to recognize that these feelings are common and perfectly normal. Here are some reasons why individuals with chronic illnesses may experience guilt:
- Burden on others: People with chronic illnesses may feel guilty about the impact their condition has on their loved ones, such as needing assistance with daily tasks, financial strain, or emotional stress. They may feel like they're a burden on their family and friends, which can lead to feelings of guilt and self-blame.
- Inability to fulfill roles: Chronic illnesses can affect a person's ability to fulfil their roles and responsibilities, whether it's at work, in relationships, or within their family. They may feel guilty for not being able to meet expectations or for having to rely on others for support.
- Perceived lack of productivity: Chronic illnesses can limit a person's ability to engage in activities they once enjoyed or pursue their goals and aspirations. They may feel guilty for not being as productive or accomplished as they were before their diagnosis.
- Self-blame: Some individuals may blame themselves for their illness, whether it's due to lifestyle factors, genetics, or other reasons. They may feel guilty for not taking better care of themselves or for somehow causing their condition.
- Comparison with others: Seeing others who appear healthy and able-bodied may trigger feelings of guilt or inadequacy in individuals with chronic illnesses. They may compare themselves to others and feel guilty for not being able to live up to societal expectations or norms.
Dealing with feelings of guilt associated with chronic illness can be challenging, but it's important to address them in a healthy and constructive way. Here are some strategies for coping with guilt:
- Practice self-compassion: Be kind to yourself and recognize that having a chronic illness is not your fault. Treat yourself with the same compassion and understanding that you would offer to a loved one in a similar situation. You have an awful lot to come to terms with and it may take some time, give yourself that time and space.
- Seek support: Talk to trusted friends or people who understand because they have been through the same experience eg in one of the support groups at the National Aspergillosis Centre, family members, or a therapist about your feelings of guilt. Sharing your emotions with others who understand can help validate your experiences and provide comfort and reassurance.
- Set realistic expectations: Adjust your expectations and goals to align with your current abilities and limitations. Focus on what you can do rather than dwelling on what you can't, and celebrate your accomplishments no matter how small. In other words to use a phrase uttered regularly in the NAC support groups - find your new normal.
- Practice gratitude: Cultivate a sense of gratitude for the support and resources available to you, as well as the things that bring you joy and fulfilment despite your illness. Focus on the positive aspects of your life rather than dwelling on feelings of guilt or inadequacy.
- Engage in self-care: Prioritize self-care activities that promote your physical, emotional, and mental well-being, such as getting enough rest, eating a balanced diet, exercising within your limits, and engaging in activities that bring you pleasure and relaxation.
- Challenge negative thoughts: Challenge negative thoughts and beliefs that contribute to feelings of guilt or self-blame. Replace them with more balanced and compassionate perspectives, reminding yourself that you are doing the best you can under challenging circumstances.
Remember that it's okay to seek professional help if you're struggling to cope with feelings of guilt or if they're significantly impacting your quality of life. A therapist or counsellor can provide additional support and guidance tailored to your specific needs and circumstances.
NOTE You may find it useful to also read our article on grief.
Graham Atherton, National Aspergillosis Centre April 2024
Tipping Point - when for a time it just all feels like TOO MUCH

Alison's story with ABPA (T'was the week before Christmas...)
As we journey through life with chronic conditions we can teach ourselves coping strategies
As the strategies work we gain a sense of achievement and I guess a pride that we can do this we can get around this but then something else happens and our planning and our strategies get sabotaged. I’ve had one of those kind of days today.
- Learn what we can achieve
- What is realistic, and what is not?
- Come up with ways of limiting how much we do at a time so that we can achieve our goals little by little.
- Pace ourselves.
Today is 21 December so only a few days before Christmas. It’s hot in New Zealand and muggy (especially in the Waikato) and I’m trying to be realistic about how much I do towards getting ready for Christmas and taking my campervan up to the family Beach House. I also want to leave the garden looking nice & tidy so that it won’t be a wilderness when I come back. Garden work can only be done in very short bursts, wearing an FFP2 Mask (very hot in the conditions). To that end, I think I was achieving except that I had developed a sty in my eye. Conservative treatment of hot packs & drops for dry eyes had not really helped
On day three, talked with the pharmacist and with my GP (via email) as to what I needed to do. I had drops of ointment on hand that was appropriate but after four days the situation was getting worse and my GP said if it didn’t improve, I’d have to go to emergency care because there are no GP appointments available. My son-in-law who is a doctor looked at it and said “That needs to be lanced you probably need to get yourself up to the eye clinic”. So after talking with my doctor’s Nurse, I went to the emergency clinic (Not the free hospital ED).
Wait time was posted as two hours, yeah that’s reasonable, but stuff happened. Emergency Clinic had two or three major emergencies come in during the course of the day & I ended up sitting there from 10:30 am until 5:15 pm. Around 2:30 I talked to the nurse at reception and asked if there was going to be somebody who would be able to deal with this, thinking that if they can’t actually do what needs to be done I should go up to the hospital. I was assured that it could be done. At 5 o’clock I saw a doctor and he decided that we needed to try a different antibiotic cream and maybe throw in some extra oral antibiotics and see how I went and if it didn’t improve in five days, to come back and then maybe we might need to send you to the eye clinic
Talk about frustrating! He had noted that I had complex health issues, I pointed out to him that my body does not respond well to infections, that it was Christmas, and that I was going north to Omaha Beach; but no that was his solution and he wasn’t listening to anything different. So my planning, trying to be careful that I didn’t push myself too far, and that I didn’t try and fit in too much, just went out the window with an entire day lost at the ER. By the time I got home, I was hungry, I was exhausted. My eye hurt so much and it could’ve been relieved in a five-minute procedure.
What to do now? I don’t seem to be sleeping, hence the writing, and I can continue the 3 hourly application of ointment to my eye throughout the night. (It’s now 3 am and I first tried to go to bed /sleep at 9:30 pm). How do I balance the need to get my eye sorted before I go North, out of the jurisdiction of my hospital to where the hospital is referred to as “Not Sure Hospital” and the travel time just to get from the beach into town to see Dr over the coming two holiday weeks will increase from 15 minutes to up to 2hours. To say nothing of how long it might take to get to NSH. (Normally an hour away) Do I risk losing another prep day and trying again to get into the Eye Clinic.? Do I risk my sight or further complications versus getting myself through Christmas not totally exhausted?
NOTE: I started this before Christmas 2023 but when I found the energy to try and finish, I couldn’t locate the file. Fast forward to March 2024 and I found it in an obscure location, a reflection of the tipping point having been reached by the time I ‘filed’ it.
As it turned out, I went back to my own Dr Surgery the next morning to talk with the Nurse who decided to get me in to see a Dr, who was very understanding and communicative. He changed the antibiotic to one that was more specific to the issue and explained the protocols needed to get me to the Eye Clinic if needed. It turned out that a recently added medication was majorly adding to the issue and once stopped I was able to get things under control & not have to go to Eye Clinic in the midst of summer holidays time.
But back to Tipping Points.
When we are dealing with Chronic Illnesses, the treatment to manage the primary diagnosis can often lead to secondary conditions, requiring yet further management treatment Energy levels are limited and ‘just one more thing’ can totally tip us. Our carefully planned and balanced strategies get totally up-ended. How do we manage that?
Let’s face it, at that moment we may just want to give up. But no, we have to acknowledge where we are at, maybe have a cry or a rant, pray and come up with a new plan while at the same time accepting that things might not turn out the way we thought they should. (On this particular day, my family invited me to join them for dinner which was very much appreciated. I also try and have precooked meals in the freezer for such situations.)
In scripture, Paul says “I have learnt to be content in plenty and in need.”
Turning our attitude around is the key. We want to think that we are in control but situations and circumstances are beyond our control.
Learning to live within the limits of Chronic Illness is a Grief Process but because there is no tangible loss as can be witnessed when someone dies, we and those around us, may not realise the implications Everyone wants to deal in the facts and the fix-it strategies. Grief is irrational and takes a great deal of working through; although it should be more accurately portrayed that we don’t work through it, as in we come out the other side, but we work to understand how this affects us and how we take it with us into new normals.
I hope this little insight will help you get through a “Tipping Point” day. Some of that process includes gaining a greater understanding of your particular mix of conditions …. But that is another subject to blog about at a later date!
Chronic illness diagnosis and grief
Many of us will be familiar with the process of grief after a loved one has died, but did you realise that the same process often happens when you are diagnosed with a chronic illness such as aspergillosis? There are very similar feelings of loss:- loss of part of your health, loss of the person you once were, loss of independence and uncertainty about the future.
- Loss of health: A chronic illness diagnosis often means facing the reality of living with a condition that will impact your physical as well as your emotional well-being. This loss of health can be significant and may require you to adjust your lifestyle, daily routines, and expectations for the future. Adjusting to a 'new normality' is difficult for some. For aspergillosis most mention that they run out of energy much more quickly as each day progresses, so they must plan to conserve energy each morning.
- Changes in identity: Chronic illness can affect how you see yourself and how others perceive you. It may require them to redefine their identity, roles, and relationships, which can be a challenging and grief-inducing process. For some of your closest relationships, there can also be a grieving process that they have to go through as well.
- Loss of independence: Depending on the severity of your aspergillosis, individuals may experience a loss of independence as they rely on others for assistance with daily tasks, medical care, or mobility. This loss can lead to feelings of frustration and sadness. This also impacts the people living closest to you e.g. your spouse or partner, as they must also come to terms with a change in your roles. Loss of independence can be emotional, physical and financial.
- Uncertainty about the future: Aspergillosis is not currently curable (though a few with aspergilloma may have the option to have surgery) and involves ongoing management and uncertainty about disease progression, treatment effectiveness, and long-term outcomes. This uncertainty can contribute to feelings of anxiety, fear, and grief about the future.
- Social and emotional impact: Chronic illness can affect relationships, social interactions, and emotional well-being. You may suddenly feel isolated as many patients describe not being listened to or understood by friends and family. You and the people you are closest to may grieve the loss of social connections, support systems, or the ability to participate in activities they once enjoyed.
It's essential for individuals diagnosed with a chronic illness to acknowledge and validate their feelings of grief and seek support from healthcare providers, loved ones, support groups, or mental health professionals as needed. Addressing and processing grief can help individuals cope with their diagnosis, adjust to life with a chronic illness, and find meaning and purpose despite the challenges they may face. Failing to properly address a grieving process can lead to a deterioration in lifestyle and depression.
How might you manage chronic disease and grief?
Managing grief after a chronic disease diagnosis can be a complex and ongoing process, but there are several strategies that can help individuals cope and adjust to their new reality. Here are some suggestions:
- Acknowledge and validate your feelings: Allow yourself to acknowledge and express your emotions, whether it's sadness, anger, fear, or frustration. Remember that grief is a natural response to loss, and it's okay to feel a range of emotions, some of which may be unexpected both in yourself and in those closest to you.
- Seek support: Don't hesitate to reach out to friends, family members, support groups, or mental health professionals for support and understanding (and medication or other treatment if needed). Talking to others who have experienced similar challenges can be validating and provide valuable insights and coping strategies. The National Aspergillosis Centre in Manchester, UK runs a collection of very busy support groups for people with all kinds of aspergillosis (Chronic Pulmonary Aspergillosis (CPA), Allergic Bronchopulmonary Aspergillosis (ABPA), Acute Invasive Aspergillosis (AIA or IA), Severe Asthma with Fungal Sensitisation (SAFS), Aspergillus bronchitis and more. The support groups are accessible via Facebook and Telegram and include Video conferencing groups twice a week. In these groups, you can meet with fellow patients who have been living with aspergillosis for many years and are very open and friendly plus NAC members of staff for any questions that you may have.
- Educate yourself: Learn as much as you can about your condition, treatment options, and self-care strategies. Understanding your illness and how to manage it can help you feel more empowered and in control of your health. The National Aspergillosis Centre runs an informative website to help guide you to the best sources of information at aspergillosis.org.
- Develop a support network: If you can, surround yourself with supportive and understanding friends and family who can offer practical help, emotional support, and encouragement. Having a strong support network can make a significant difference in coping with chronic illness. Sometimes impartial professional help from a counsellor can be beneficial when making decisions.
- Take care of yourself: Prioritize self-care and make your physical and emotional well-being a priority. This may include getting enough rest, eating a balanced diet, engaging in regular exercise (as appropriate), practicing relaxation techniques, and finding activities that bring you joy and fulfilment.
- Set realistic goals: Adjust your expectations and set realistic goals for yourself based on your current abilities and limitations. Break larger goals into smaller, manageable steps, and celebrate your achievements along the way. Many patients find it helps to get through the day better if they use spoon theory to better manage the amount of energy they may have each day.
- Practice mindfulness and acceptance: Practice mindfulness techniques, such as deep breathing, meditation, or mindfulness exercises, to help you stay grounded and present in the moment. Acceptance doesn't mean giving up hope, but rather acknowledging and embracing your current reality while focusing on what you can control.
- Seek professional help if needed: If you're struggling to cope with grief, anxiety, depression, or other mental health concerns, don't hesitate to seek help from a mental health professional. Therapy can provide a safe space to explore your feelings, develop coping strategies, and find support.
Remember that managing grief and adjusting to life with a chronic illness is a journey, and it's okay to seek help and support along the way. Be patient with yourself, practice self-compassion, and take things one day at a time.
Lived experience from Alison
First, we might need to define what Grief is..
We use the word grief but what is our understanding of it? I think that definition & understanding change as we experience more of life’s difficulties. One of the definitions that is used is “A tangled web of emotions”. Anger, sorrow, disappointment, tears, frustration, loss of identity, mood swings, confusion, depression, resignation. The list is almost endless and it is not in any neat order or timeframe progression.
Another factor in our consideration is guilt, some of which is generated by our acceptance and adherence to what have become “social norms”. There seems to be a denial of the inevitability of death & deterioration of our physical bodies. So when these factors become very evident in our daily lives we want & expect to be able to fix them and avoid the consequences. When this doesn’t happen, we grieve &/or feel guilty that we can’t meet those expectations So we need to “Process our Grief” but again; what does that phrase mean?
For every individual, it will take different forms because every situation is unique to that individual. the relationships involved, the extent of the disease, how it manifests, and how it progresses. How we view life. Processing our Grief requires the difficult discipline of looking at what our core beliefs on life are, what are the losses and shifting those concepts from 'head knowledge' to a 'heart acceptance' as well as adjusting to practical implications & changes. All of which will take time and energy, and is exhausting. From my experience I can suggest the following:
- Having a Support Group filled with people who have walked the path before you is a huge help.
- Reading articles about your condition and how to manage it.
- Talking with a friend.
- Journaling the process is also useful as you can look back and see progress and things that you were going to try to do but haven’t yet evaluated. This can also be very useful to refer to when talking to your health professional.
All these activities will help us come to terms with our Chronic Disease.
Another factor that comes into dealing with a Chronic Illness is the nature of the condition and its perceived significance in society. Before I got the Aspergillosis diagnosis, we were told that it was Lung Cancer. When that changed to Aspergillosis my daughter (Palliative Care Physician ) said that the Cancer diagnosis would have been easier! The reason for this is that Cancer is a socially understood condition, there are extensive supports in place, major fundraising and awareness and people rally around. There is a clear pathway towards treatment and expectations. (Similarly with Heart Disease & one or two other well-funded conditions).
Lung conditions on the other hand have a stigma that you haven’t looked after your lungs, therefore you are to blame and/or it just means you don’t breathe very well but it can be managed and doesn’t have a huge impact on your life. Think about how the Anti Smoking Campaigns are presented.
Chronic lung conditions also have a higher prevalence where living conditions are poor and I see that as influencing how much time and resources can be put into awareness campaigns and research.
Thank you to NAC with the National Aspergillosis Support (run by the NHS) & Aspergillosis Trust Support (run by aspergillosis patients on Facebook) for reliable information, guidelines, research developments and patient stories www.aspergillosis.org www.aspergillosistrust.org
Useful links on grief and guilt
MIND 'What does grief feel like?'
Psychology Today 'Chronic illness and grief'
Arthritis Foundation 'Grief & Chronic illness'
NHS Every Mind Matters 'Mental health and physical illness'
